MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Kymera Therapeutics Inc

Closed

SectorHealthcare

33.46 8.81

Overview

Share price change

24h

Current

Min

30.5

Max

33.65

Key metrics

By Trading Economics

Income

-8.3M

-71M

Sales

3.7M

7.4M

EPS

-0.89

Profit margin

-956.884

Employees

188

EBITDA

-8.3M

-69M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+92.92% upside

Dividends

By Dow Jones

Next Earnings

9 maj 2025

Market Stats

By TradingEconomics

Market Cap

-523M

1.8B

Previous open

24.65

Previous close

33.46

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Kymera Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 lis 2024, 03:00 UTC

Top News

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 lip 2024, 09:05 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Peer Comparison

Price change

Kymera Therapeutics Inc Forecast

Price Target

By TipRanks

92.92% upside

12 Months Forecast

Average 55.56 USD  92.92%

High 72 USD

Low 49 USD

Based on 11 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

25.43 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.